$Orchard Therapeutics(ORTX.US)$Orchard Therapeutics (ORTX), recently acquired by Kyowa Kirin (OTCPK:KYKOY), has set its newly FDA-approved rare disease therapy Lenmeldy at a wholesale price of $4.25M on Wednesday, making one-time gene therapy the world's costliest medicine. Early this week, the FDA approved Lenmeldy as the first U.S. treatment for early-onset metachromatic leukodystrophy (MLD), a rare metabolic disorder. The...
$Orchard Therapeutics(ORTX.US)$(Kyowa Kirin) 📣 Receives FDA Approval of Lenmeldy (atidarsagene autotemcel) 🎉 ⇒ Only therapy for children with early-onset metachromatic leukodystrophy (MLD) in US 👏 ⇒ Lenmeldy known as Libmeldy in EU
$Orchard Therapeutics(ORTX.US)$Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome 3 MINUTES AGO, 7:00 AM EST VIA GLOBENEWSWIRE
Pre-Market Stock Movers Gapping up Shares of$UWM Holdings(UWMC.US)$rose 4.3% in premarket trading after a BTIG upgrade to buy from neutral. BTIG said the valuation for the parent company of United Wholesale Mortgage does not reflect the upside from a potential stabilization in interest rates. $Orchard Therapeutics(ORTX.US)$soared more than 98% on news that the company would be acquired by Japanese pharmaceutical Ky...
SpyderCall : 很好的東西像往常一樣